	US 7,468,391 B2
	Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
Jayasree Vasudevan, Anaheim, Calif. (US); Rong Yang, Viejo, Calif. (US); Liming Wang, Irvine, Calif. (US); Xiaoxia Liu, Nashua, N.H. (US); Kwok-Yin Tsang, Irvine, Calif. (US); Ling Li, Irvine, Calif. (US); Janet Takeuchi, Anaheim, Calif. (US); Thong Vu, Garden Grove, Calif. (US); Richard Beard, Newport Beach, Calif. (US); Smita Bhat, Irvine, Calif. (US); and Roshantha A. Chandraratna, Laguna Hills, Calif. (US)
Assigned to Allergan, Inc., Irvine, Calif. (US)
Filed on Dec. 13, 2004, as Appl. No. 11/10,953.
Claims priority of provisional application 60/530601, filed on Dec. 17, 2003.
Prior Publication US 2005/0187298 A1, Aug. 25, 2005
Int. Cl. A01N 31/00 (2006.01); A61K 9/00 (2006.01); A61K 31/415 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01)

U.S. Cl. 514—567 [424/400; 424/404]

12 Claims

1. A method for treating an individual having a retinoid responsive skin disorder selected from the group consisting of acne, psoriasis, eczema, atopic dermatitis, Pityriasis rubra pilaris, multiple basal cell carcinomasactinic keratoses, arsenic keratoses, ichthyoses, Darriers disease, lichen planus, glucocorticoid damage, microbial infection of the skin, excessive pigmentation of the skin, and photodamage of the skin, comprising administering to said individual an effective amount of a selective CYP26A inhibitor having a formula selected from:

wherein,

R₁=R₂=Me;

X=O or S; and

Y=CH₂N(Me)(cyc-Pr), OR, COOR, wherein R=lower alkyl, cycloalkyl; or

R₁=Me;

R₂=H;

X=H(C)CH₂N(Me)(cyc-Pr); and

Y=OR, COOR wherein R=lower alkyl, or cycloalkyl; or

R₁=Me;

R₂=H;

X=C═O; and

Y=alkenyl,

or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof.